Epygenix Therapeutics, Inc., a privately-held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the first patient has been enrolled in a Phase 2, 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 as Adjunctive Therapy in Children with Dravet Syndrome. This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting 24 patients to complete the study. Detailed study information is now available at clinicaltrials.gov. and dravetfoundation.org.
Dr. Scott C. Baraban, Ph.D., Endowed Chair in Neuroscience Research at UCSF and Chair of the Scientific Advisory Board at Epygenix Therapeutics, Inc. issued a joint comment that "First patient enrollment is an extremely exciting culmination and validation of our zebrafish-based drug discovery platform. Our early promise to find new drugs for children suffering with Dravet Syndrome in a rapid and efficient manner is now coming to fruition. Working with Epygenix to move these preclinical discoveries to the clinic, in only a few short years, is a prime example of our 'aquarium-to-bedside' philosophy."